Divi nevis trīs
Apskatīt komentārus (0)
11.09.2016
GlaxoSmithKline ierosina ieviest jaunu HIV-infekcijas ārstēšanas shēmu
Farmācijas kompānija GlaxoSmithKline (Lielbritānija) cenšas mainīt HIV-infekcijas ārstēšanas standartus, piedāvājot tradicionālās trīs preparātu shēmas vietā izmantot divus preparātus - Tivicay no ViiV Healthcare kombinācijā ar Edurant no Janssen vai jebkuru lamivudīna ģenēriķi. GlaxoSmithKline cenšas pierādīt, ka Tivicay apvienojumā ar citu antivīrusu preparātu var dot tādu pašu pozitīvu rezultātu kā tradicionālā HIV terapija, izmantojot trīs preparātus. Pēc GSK prognozēm, tikai ceturtdaļas pacientu, kas lieto trīspakāpju terapiju, pāriešana uz ārstēšanas shēmu Tivicay+lamivudīns, piecos gados ļaus HIV infekcijas ārstēšanai ieekonomēt vairāk nekā 3 miljardus dolāru.
****************
<... The British drugmaker is looking to upend the standard, three-med approach to HIV treatment with a two-drug combo centered on Tivicay, the latest pill from Glaxos ViiV Healthcare unit.
The pharma giant has embarked on a number of hefty clinical trials aiming to demonstrate that pairing Tivicay with just one other HIV-fighter can get the job done just as well as a triple therapy can, The Wall Street Journal reports. In one set of studies, GSK is examining Tivicay in tandem with Edurant from Johnson & Johnsons Janssen unit; in another, Tivicay is joining forces with the long-used generic med 3TC.
And more two-drug trials on the way. GSK intends to launch a late-stage trial fusing an injectable version of Tivicay with Edurant, which has already proven itself as effective as a three-drug medley in patients whose virus had previously been suppressed by lead-in period of triple therapy.
So far, Glaxo has reason to be hopeful, the Journal notes. In one small, 48-week study, the Tivicay-3TC one-two punch suppressed HIV levels in 18 of 20 previously untreated sufferers. ...>
Atpakaļ